why choose us

First received: November 16, 2022

Clinical Trial: CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Glioblastoma Multiforme of Brain

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Study to Evaluate CHM-1101, a CAR T-Cell Therapy With a Chlorotoxin Tumor-Targeting Domain for Patients With Matrix Metallopeptidase 2 Positive (MMP2+) Recurrent or Progressive Glioblastoma

Brief Summary: This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).

Read more